Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeting the HGF/c-Met axis: state of play.

× No keyword cloud information.

17 in total

1. c-MET: an exciting new target for anticancer therapy.

Authors: Johann S de Bono; Timothy A Yap
Journal: Ther Adv Med Oncol Date: 2011-11 Impact factor: 8.168

Review 2. Envisioning the future of early anticancer drug development.

Authors: Timothy A Yap; Shahneen K Sandhu; Paul Workman; Johann S de Bono
Journal: Nat Rev Cancer Date: 2010-06-10 Impact factor: 60.716

Review 3. Tumor-targeted drug delivery with aptamers.

Authors: Y Zhang; H Hong; W Cai
Journal: Curr Med Chem Date: 2011 Impact factor: 4.530

Review 4. Molecular targeted therapy for hepatocellular carcinoma: current and future.

Authors: Jung Woo Shin; Young-Hwa Chung
Journal: World J Gastroenterol Date: 2013-10-07 Impact factor: 5.742

5. Future directions in the evaluation of c-MET-driven malignancies.

Authors: Johann S de Bono; Timothy A Yap
Journal: Ther Adv Med Oncol Date: 2011-11 Impact factor: 8.168

6. Anthraquinone Derivatives as Potent Inhibitors of c-Met Kinase and the Extracellular Signaling Pathway.

Authors: Zhongjie Liang; Jing Ai; Xiao Ding; Xia Peng; Dengyou Zhang; Ruihan Zhang; Ying Wang; Fang Liu; Mingyue Zheng; Hualiang Jiang; Hong Liu; Meiyu Geng; Cheng Luo
Journal: ACS Med Chem Lett Date: 2013-02-25 Impact factor: 4.345

7. Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity.

Authors: Vishnu C Ramani; Yang Yang; Yongsheng Ren; Li Nan; Ralph D Sanderson
Journal: J Biol Chem Date: 2010-12-03 Impact factor: 5.157

Review 8. Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalities.

Authors: Axel Bex; James Larkin; Christian Blank
Journal: Curr Oncol Rep Date: 2011-06 Impact factor: 5.075

9. Ligand-independent activation of MET through IGF-1/IGF-1R signaling.

Authors: Andreas Varkaris; Sanchaika Gaur; Nila U Parikh; Jian H Song; Farshid Dayyani; Jung-Kang Jin; Christopher J Logothetis; Gary E Gallick
Journal: Int J Cancer Date: 2013-04-17 Impact factor: 7.396

10. Celastrol exerts synergistic effects with PHA-665752 and inhibits tumor growth of c-Met-deficient hepatocellular carcinoma in vivo.

Authors: Hong-Lei Jiang; Jun-Zhe Jin; Dan Wu; Dong Xu; Guo-Fu Lin; Hao Yu; Dong-Yan Ma; Jian Liang
Journal: Mol Biol Rep Date: 2013-05-07 Impact factor: 2.316